In a significant stride towards enhancing access to advanced cancer treatment, Amethyst Radiotherapy Group has secured a landmark €300 million financing agreement with Credit funds managed by Ares Management Corporation (“Ares”), a leading global alternative investment manager.
This investment positions Amethyst as a leading player in the European oncology sector, as it continues to accelerate its expansion. The facilities secured will support strategic acquisitions and capacity enhancement, positioning Amethyst firmly among the frontrunners to redefine the European cancer treatment landscape.
Abolon’s prepared the commercial vendor due diligence of Amethyst for the successful refinancing, highlighting once more Abolon’s strong expertise in diagnosing and treating oncological diseases.
With separate teams, Abolon advises clients on corporate and financing transactions incl. commercial due diligence, vendor due diligence, strategy development and M&A/corporate finance. Our clients benefit from our experience after more than 200 C(V)DD projects and M&A transactions.
English 
Deutsch